Signatera Shows Strong Prognostic Value in Largest Lung Cancer MRD Study
NTRA has more than doubled off its 52-week low of $157.425 on elevated volume (1.8× avg).
Summary
Natera presented data from the largest MRD study in lung cancer at WCLC 2026, showing Signatera strongly predicts recurrence-free survival in 1,129 resected stage 1-3 NSCLC patients. Early post-surgical Signatera-positivity was associated with significantly worse RFS, with a 25% higher absolute 3-year RFS for Signatera-negative patients. Signatera-positive patients had approximately 5X the risk of recurrence or death during surveillance. This is the first report of this dataset and adds to a series of positive Signatera validation studies across tumor types. The scale and consistency of the data could support broader adoption in lung cancer, a large market. Natera's stock is trading near its 52-week high, reflecting strong momentum in its oncology franchise.
At the time of this announcement, NTRA was trading at $367.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.8B. The 52-week trading range was $157.43 to $366.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.